Skip to main content

ADMINISTRACION DE FARMACOS ESPECIFICOS DE LA CPT1 CENTRAL: UNA NOVEDOSA ESTRATEGIA BASADA EN NANOMEDICINA PARA COMBATIR OBESIDAD Y CANCER

PCI2018-092997

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos Programación Conjunta Internacional
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSITAT INTERNACIONAL DE CATALUNYA,FUNDACIO PRIVADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Carnitine palmitoyltransferase 1C negatively regulates the endocannabinoid hydrolase ABHD6 in mice, depending on nutritional status

  • Miralpeix Monclús, Cristina
  • Reguera, Ana Cristina
  • Fosch, Anna
  • Casas, Maria
  • Lillo, Jaume
  • Navarro, Gemma
  • Franco, Rafael
  • Casas, Josefina
  • Alexander, Stephen P.H.
  • Casals i Farré, Núria
  • Rodríguez-Rodríguez, Rosalía
Fundació La Marató de TV3, Grant/Award Numbers: 87/C/2016, Grant 87/C/2016 to N.C.; Agència de Gestió d'Ajuts Universitaris i de la Recerca (AGAUR) in Catalonia; Joint Bilateral Project Japan-Spain/AEI, Grant/Award Number: PCI2018-092997/AEI to R.R.-R.; Fondo Europeo de Desarrollo Regional (FEDER), Grant/Award Number: SAF2017-83813-C3-3-R to N.C. and R.R.-R.; Agencia Estatal de Investigación (AEI); Ministerio de Economía, Industria y Competitividad (MINECO); Department of Psychological and Brain Sciences, Indiana University Bloomington (USA); Research Unit of BioActive Molecules (Institut de Química Avançada de Catalunya, IQAC), Background and Purpose: The enzyme α/β‐hydrolase domain containing 6 (ABHD6), a new member of the endocannabinoid system, is a promising therapeutic target against neuronal‐related diseases. However, how ABHD6 activity is regulated is not known. ABHD6 coexists in protein complexes with the brain‐specific carnitine palmitoyltransferase 1C (CPT1C). CPT1C is involved in neuro‐metabolic functions, depending on brain malonyl–CoA levels. Our aim was to study CPT1C–ABHD6 interaction and determine whether CPT1C is a key regulator of ABHD6 activity depending on nutritional status. Experimental Approach: Co‐immunoprecipitation and FRET assays were used to explore ABHD6 interaction with CPT1C or modified malonyl–CoA‐insensitive or C‐terminal truncated CPT1C forms. Cannabinoid CB1 receptor‐mediated signalling was investigated by determining cAMP levels. A novel highly sensitive fluorescent method was optimized to measure ABHD6 activity in non‐neuronal and neuronal cells and in brain tissues from wild‐type (WT) and CPT1C–KO mice. Key Results: CPT1C interacted with ABHD6 and negatively regulated its hydrolase activity, thereby regulating 2‐AG downstream signalling. Accordingly, brain tissues of CPT1C–KO mice showed increased ABHD6 activity. CPT1C malonyl–CoA sensing was key to the regulatory role on ABHD6 activity and CB1 receptor signalling. Fasting, which attenuates brain malonyl–CoA, significantly increased ABHD6 activity in hypothalamus from WT, but not CPT1C–KO, mice. Conclusions and Implications: Our finding that negative regulation of ABHD6 activity, particularly in the hypothalamus, is sensitive to nutritional status throws new light on the characterization and the importance of the proteins involved as potential targets against diseases affecting the CNS., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Hypothalamic regulation of obesity

  • Rodríguez-Rodríguez, Rosalía
  • Miralpeix , Cristina
This work was supported by the Spanish Ministerio de Economía, Industria y Competitividad (MINECO), Agencia Estatal de Investigación (AEI), and Fondo Europeo de Desarrollo Regional (FEDER) (Grants PCI2018-092997/AEI to R.R.-R.; PID2020-114953RB-C22 to R.R.-R. by MCIN/AEI/10.13039/501100011033)., Obesity has now reached pandemic proportions and represents a major socioeconomic and health problem in our societies. Up to now, obesity has been considered a medical issue only in high-income countries, but this disease is now dramatically on the rise in low- and middle-income countries, particularly in urban settings, affecting both adults and the pediatric population [1]. The simplest definition of overweight and obesity is an excessive accumulation of fat due to an imbalance between the energy in and the energy out, and this adiposity represents a risk to health [1]. But the whole picture is more complex than this, and obesity is a marker of a serious metabolic dysregulation that involves several diseases such as type 2 diabetes, cancer, cardiovascular pathologies, and most recently for COVID-19 infection [1,2]. Since the current approaches to combatting obesity and its complications have limited clinical effectiveness, gaining insight into the cellular and molecular basis of obesity could lay the foundations for the development of new strategies to prevent metabolic disruption and to treat this somewhat unaddressed medical issue. In the last few decades, it has been strongly demonstrated that the hypothalamus is the master regulator of energy homeostasis. The hypothalamus contains hormone- and nutrient-sensing nuclei that organize central and peripheral responses for maintaining normal body weight, food intake, energy expenditure, and nutrient partitioning. Within the hypothalamus, specialized sub-populations of neurons are connected to each other and to various extrahypothalamic regions to coordinate energy balance. Evidence has also highlighted the participation of non-neuronal populations (i.e., microglia and astrocytes), and even the interesting cross-talk between these types of brain cells, whose disruption leads to insulin resistance and obesity. In this Special Issue, we report on the most recent insights into the hypothalamic circuitries and pathways involving neurons [3,4,5,6,7], astrocytes [8,9], and microglia [10,11] in obesity development and associated complications. The emerging contribution of astrocyte–neuron [9] and microglia–neuron cross-talks [12] in the hypothalamus and the contribution of microbiota and the gut-brain axis controlling food intake and energy homeostasis [13] are also presented in this Special Issue., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pomace olive oil concentrated in triterpenic acids restores vascular function, glucose tolerance and obesity progression in mice

  • Claro-Cala, Carmen Maria
  • Quintela, Jose Carlos
  • Pérez-Montero, Marta
  • Miñano, Javier
  • Alvarez de Sotomayor, María
  • Dolores Herrera, María
  • Rodríguez-Rodríguez, Rosalía
This work was supported by the Spanish Ministerio de Economía, Industria y Competitividad (MINECO), Agencia Estatal de Investigación (AEI), and Fondo Europeo de Desarrollo Regional (FEDER) (Grants SAF2017-82813-C3-3-R and PCI2018-092997/AEI to R.R.-R.)., Pomace olive oil, an olive oil sub-product, is a promising source of bioactive triterpenoids such as oleanolic acid and maslinic acid. Considering the vascular actions of pomace olive oil and the potential effects of the isolated oleanolic acid on metabolic complications of obesity, this study investigates for the first time the dietary intervention with a pomace olive oil with high concentrations of the triterpenic acids (POCTA), oleanolic and maslinic acid, during diet-induced obesity in mice. The results demonstrate that obese mice, when switched to a POCTA-diet for 10 weeks, show a substantial reduction of body weight, insulin resistance, adipose tissue inflammation, and particularly, improvement of vascular function despite high caloric intake. This study reveals the potential of a functional food based on pomace olive oil and its triterpenic fraction against obesity progression. Our data also contribute to understanding the health-promoting effects attributable to the Mediterranean diet., info:eu-repo/semantics/acceptedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Molecular Mechanisms Underlying the Effects of Olive Oil Triterpenic Acids in Obesity and Related Diseases

  • Claro Cala, Carmen Mª|||0000-0001-9943-405X
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • Zagmutt, Sebastian|||0000-0001-6050-4452
  • Rodríguez Rodríguez, Rosalía|||0000-0002-6908-7197
Dietary components exert protective effects against obesity and related metabolic and cardiovascular disturbances by interfering with the molecular pathways leading to these pathologies. Dietary biomolecules are currently promising strategies to help in the management of obesity and metabolic syndrome, which are still unmet medical issues. Olive oil, a key component of the Mediterranean diet, provides an exceptional lipid matrix highly rich in bioactive molecules. Among them, the pentacyclic triterpenic acids (i.e., oleanolic acid) have gained clinical relevance in the last decade due to their wide range of biological actions, particularly in terms of vascular function, obesity and insulin resistance. Considering the promising effects of these triterpenic compounds as nutraceuticals and components of functional foods against obesity and associated complications, the aim of our review is to decipher and discuss the main molecular mechanisms underlying these effects driven by olive oil triterpenes, in particular by oleanolic acid. Special attention is paid to their signaling and targets related to glucose and insulin homeostasis, lipid metabolism, adiposity and cardiovascular dysfunction in obesity. Our study is aimed at providing a better understanding of the impact of dietary components of olive oil in the long-term management of obesity and metabolic syndrome in humans.